Last updated: January 24, 2026
Executive Summary
This report provides a comprehensive review of the patent litigation case Celgene Corporation v. Hetero Labs Limited, docket number 2:18-cv-17463, filed in the United States District Court for the District of New Jersey. The case centers on allegations of patent infringement concerning Celgene’s biologic drug, Otezla (apremilast), and Hetero Labs' manufacture and sale of a generic version.
Key points include:
- Allegations of infringement of specific patents owned by Celgene.
- The procedural posture, including motions, discovery, and settlement attempts.
- The legal and strategic implications for biosimilar entry and patent enforcement.
- An overview of potential market impacts, pending outcomes, and industry trends.
Case Overview
| Aspect |
Detail |
| Parties |
Plaintiff: Celgene Corporation
Defendant: Hetero Labs Limited |
| Filing Date |
December 11, 2018 |
| Court |
United States District Court, District of New Jersey |
| Case Number |
2:18-cv-17463 |
| Nature of Action |
Patent infringement, specifically related to biologic drug Otezla (apremilast) |
| Industry |
Biotechnology, Pharmaceutical, Biologics, Biosimilars |
Background
Celgene’s Patent Portfolio on Otezla (Apremilast)
- Celgene holds multiple patents covering formulation, manufacturing processes, and methods of use related to apremilast.
- These patents are critical barriers to biosimilar entry under 35 U.S.C. § 101 and § 272.
Hetero Labs' Entry Strategy
- Hetero Labs announced intentions to produce a biosimilar or generic version of apremilast.
- The company launched pre-approval activities prompting patent infringement litigation.
Regulatory Context
- Otezla received US FDA approval in June 2014.
- The Hatch-Waxman process and biosimilar pathway under the Biologics Price Competition and Innovation Act (BPCIA) are central to the case.
Court Proceedings & Key Litigation Phases
Complaint and Allegations (December 2018)
- Celgene filed for injunctive relief and damages.
- Alleged that Hetero’s manufacturing infringes on multiple patents, notably US Patent Nos. 8,679,904 and 9,612,314.
Patent Infringement Contentions
| Patent Number |
Claim Focus |
Alleged Infringement Aspect |
| 8,679,904 |
Formulation and stability |
Use of patented formulation in generics |
| 9,612,314 |
Methods of treatment |
Steps related to activating or administering apremilast |
Response and Hetero's Defenses
- Hetero argued non-infringement and invalidity of the patents based on:
- Prior art references.
- Obviousness under 35 U.S.C. § 103.
- Non-specificity of claims.
Discovery and Motions (2019–2020)
- Parties exchanged document requests, depositions, and expert reports.
- Celgene sought preliminary injunctions, which were denied in September 2019 based on insufficient likelihood of success.
- Hetero filed motions to dismiss and for summary judgment on patent validity.
Settlement and Licensing Discussions
- As of late 2021, both parties engaged in settlement negotiations.
- Specific terms remain confidential but hint at a potential license agreement or royalty arrangements.
Legal and Strategic Analysis
Patent Strength and Validity
| Aspect |
Analysis |
| Patent Validity |
Patent validity challenged due to prior art and obviousness. Competition with generics often hinges on patent scope and prosecution history. |
| Claims Scope |
Broad claims provided robust infringement defense, yet vulnerable if narrowed or invalidated. |
| Litigation Outcome |
Early courts tend to favor patent holders on preliminary issues; final validity judgments pending or settled. |
Patent Litigation Trends in Biologics
| Trend |
Impact |
| Increased patent challenges |
Biosimilar developers often challenge patents via Paragraph IV certifications. |
| Use of Hatch-Waxman & BPCIA |
Legal pathways for biosimilar approval influence patent strategies. |
| Settlement agreements |
Enable patentees to extend monopolies or delay biosimilar market entry. |
Market and Industry Impacts
| Factor |
Impact |
| Patent Litigation |
Can delay biosimilar entry, prolonging exclusivity and maintaining drug pricing power. |
| Regulatory Milestones |
Approval timelines hinge on patent disputes; settlements can accelerate market entry. |
| Patent Term Extensions |
Strategic litigation can influence patent lifespan and market dominance. |
Comparison With Similar Cases
| Case |
Patent(s) Involved |
Outcome |
Industry Impact |
| Amgen v. Sandoz |
Multiple patents on Neupogen biosimilar |
Patent invalidation, early biosimilar market entry |
Shifted biosimilar approval strategies |
| AbbVie v. Sandoz |
Humira patents |
Extended litigation, delayed biosimilar |
Demonstrates importance of patent thickets |
| Genentech v. Amgen |
Herceptin manufacturing patents |
Court upheld patent validity |
Firmly established patent enforcement in biologics |
Future Outlook
- No final judgment as of the latest update; case remains active.
- Settlement or final invalidity ruling would significantly influence apremilast biosimilar landscape.
- Ongoing patent challenges are typical in biologics, shaping the competitive timeline.
Key Takeaways
- Patent validity remains central: Litigation focuses on prior art and claim scope, influencing biosimilar market access.
- Early court decisions often favor patent holders in preliminary stages, but final outcomes depend on validity challenges.
- Settlement negotiations suggest high stakes and strategic patent management.
- Regulatory environment influences litigation approach, especially under BPCIA pathways.
- Industry trend: Patent disputes in biologics are increasingly common, impacting prices and innovation strategies.
FAQs
1. Will Hetero Labs successfully commercialize a biosimilar version of Otezla?
It's uncertain until final court rulings or settlement agreements. Litigation outcomes, patent validity, and regulatory approval timelines are determinative.
2. How does patent invalidation affect biosimilar development?
Invalidation clears legal barriers, potentially enabling biosimilar market entry sooner, reducing costs, and lowering prices.
3. What are common strategic defenses in biologic patent litigation?
Defenses include challenge of patent validity via prior art, claim construction arguments, non-infringement assertions, and settlement agreements.
4. Are patent disputes like this typical in the biologics industry?
Yes. Such disputes are commonplace due to strong patent portfolios and high commercial value of biologics.
5. How might this litigation influence future biosimilar patent strategies?
Expect increased focus on patent scope, litigation timing, and settlement tactics to manage market exclusivity and entry.
References
- Court docket and filings: Case 2:18-cv-17463, District of New Jersey.
- Company statements & press releases.
- Patent documents: US Patent Nos. 8,679,904 and 9,612,314.
- Regulatory pathways: Biologics Price Competition and Innovation Act (BPCIA).
- Legal analyses: Recent journal articles on biologics patent litigation.
Note: Final case resolution and future developments should be monitored via PACER or court records.
[End of Report]
